CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 50 target
Drug / intervention
Lactobacillus plantarum 276 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04223388
NCT04223388N/AUnknown
CompareCT.gov

A Randomized, Double-blind, Placebo-controlled, Parallel, Research Study to Investigate the Safety and Efficacy of a Probiotic Lactobacillus Plantarum 276 (Lp276) on Gastrointestinal Health in Healthy Adults

Church & Dwight Company, Inc.·interventional·Posted Jan 10, 2020·Updated Jan 10, 2020

In Brief

A clinical study evaluating Lactobacillus plantarum 276 and Placebo for Gastrointestinal Health and Healthy. Targeting 50 participants across 1 site.

Detailed Summary

Eligible participants will be randomized and receive either the probioic or placebo supplement to consume daily for 28-days. Three check-in visits will occur every 7 days of study participation. Participants will be expected to complete a daily study diary documenting their investigational product use/adverse events and a daily bowel habits diary documenting each bowel movement. Blood samples, stool samples, and questionnaires will be completed for study outcome analysis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastrointestinal Health, Healthy
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

N/AUnknownOverdue
2020202120222023202420252026
First PostedJan 10, 2020
Enrollment StartDec 18, 2019
Primary CompletionApr 1, 2020
TodayJul 1, 2026
Enrollment to primary: 3 monthsPosted 6.5 years ago

Interventions

Lactobacillus plantarum 276dietary

5 Billion CFU/dose, serving size = 1 capsule/day

Placeboother

Placebo product, serving size = 1 capsule/day